Vulvodynia (Investigational)
Highly investigational adjunct for chronic vulvodynia refractory to conventional therapy; case reports only; pelvic floor PT, topical therapy, and TCAs remain primary.
Краткая информация для пациента
- Есть ли FDA-допуск для этого показания?
- Not FDA-cleared for vulvodynia. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is highly investigational, paraspinal placement only.
- Какие доказательства существуют?
- Tier C (highly investigational). Only isolated case reports describe sacral / paraspinal application; there are no randomized controlled trials. Evidence-based management per ACOG and ISSVD includes pelvic floor physical therapy (a cornerstone), topical lidocaine 5 percent or topical estrogen for hormonal-mediated vestibulodynia, tricyclic antidepressants (amitriptyline, nortriptyline), gabapentin or pregabalin, and selective surgical vestibulectomy for refractory provoked vestibulodynia. Cognitive behavioral therapy and sex therapy are valuable adjuncts.
- Основные риски
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness over the sacrum / lower back for 5 to 10 days
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Worsening of vulvar pain in the first 24 hours
- Small permanent scars at bite sites
- Delay or replacement of pelvic floor physical therapy or evidence-based pharmacotherapy
- Dangerous mucosal contamination if any vulvar / vaginal placement is attempted
- Кому не следует это рассматривать
- Patients who are pregnant
- Any consideration of vulvar, vaginal, or perineal placement (mucosal placement is absolutely contraindicated)
- Patients with active vulvovaginal infection (candidiasis, bacterial vaginosis, herpes) or dermatosis (lichen sclerosus, lichen planus, lichen simplex chronicus)
- Patients with untreated comorbid depression or anxiety contributing to pain perception
- Patients who have not engaged with pelvic floor physical therapy
- Patients on anticoagulants, with hemophilia, or with severe anemia
- О чём спросить врача
- Has my vulvodynia been classified (localized vs generalized, provoked vs spontaneous, primary vs secondary)?
- Have other causes been ruled out (lichen sclerosus, lichen planus, atrophic vulvitis, recurrent yeast / BV, infection, pudendal neuralgia)?
- Am I engaged with a pelvic floor physical therapist?
- Have I tried topical lidocaine, topical estrogen (if appropriate), TCAs, or gabapentinoids?
- If provoked vestibulodynia is refractory, am I a candidate for surgical vestibulectomy?
- Has the practitioner explained that NO vulvar / vaginal placement is permitted — only sacral / paraspinal?
- What is the practitioner's experience and Aeromonas-prevention plan?
- Когда срочно обратиться за медицинской помощью
- New severe vulvar pain with ulceration, blistering, or discharge (rule out herpes, candida, bacterial infection)
- Severe pelvic pain unrelated to typical vulvodynia
- Sudden urinary retention, severe dysuria, or hematuria
- Spreading redness, warmth, pus, or red streaks on the lower back (cellulitis)
- Bleeding from a bite site lasting more than 24 to 48 hours
- Fever above 38.0 C / 100.4 F or chills
- Hives, throat tightness, or breathing difficulty
Что это НЕ означает
- This is not FDA-cleared for vulvodynia.
- Isolated case reports do NOT establish efficacy versus pelvic floor PT, topical lidocaine, TCAs, or gabapentinoids.
- Mechanism rationale (anti-inflammatory neuropathic modulation) does NOT establish clinical efficacy.
- Leech therapy is NEVER applied to the vulva, vagina, or perineum — those are absolute contraindications.
- Leech therapy is not a substitute for pelvic floor physical therapy or evidence-based pharmacotherapy.
Перекрёстные ссылки безопасности
Clinical Profile
- Category
- gynecologic
- ICD-10
- N94.819, N94.818
- Safety tier
- high
Evidence Summary
Vulvodynia diagnosis follows ISSVD 2015 terminology (localized vs generalized, provoked vs spontaneous), and management per ACOG and ISSVD includes pelvic floor physical therapy, topical lidocaine or estrogen, tricyclic antidepressants, gabapentin, and selective surgical vestibulectomy. No controlled clinical trial of leech therapy for vulvodynia has been published; use is investigational and mechanistic only, and the honest evidence grade is D. Vulvar leech application is not appropriate due to mucosal anatomy; only paraspinal (lumbar/sacral) application is even theoretically considered, and any neuropathic-pain-modulation rationale is unproven. Pelvic floor dysfunction is the dominant biomechanical contributor and requires pelvic PT.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Wollina U (2008)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Pregnancy
- Any vulvar, vaginal, or perineal placement (mucosal contraindication)
- Active vulvovaginal infection or dermatosis
- Untreated comorbid depression or anxiety
Related Conditions
Lactational Mastitis (Non-Suppurative)
Investigational adjunctive use for non-suppurative lactational mastitis; case-series evidence for resolution of induration and reduced antibiotic days.
Endometriosis-Related Pelvic Pain
Investigational adjunctive use for chronic endometriosis-related pelvic pain; very limited evidence. Not a substitute for hormonal or surgical management.
Primary Dysmenorrhea
Investigational use for primary dysmenorrhea refractory to NSAIDs and hormonal contraception; small case series.
Chronic Pelvic Pain Syndrome (Non-Specific)
Investigational use for non-specific chronic pelvic pain syndrome; case-series evidence for symptom reduction within multimodal management.